Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Identifieur interne : 003634 ( Main/Exploration ); précédent : 003633; suivant : 003635Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Auteurs : Zhongyu Zhu [États-Unis] ; Samitabh Chakraborti [États-Unis] ; Yuxian He [États-Unis] ; Anjeanette Roberts ; Tim Sheahan [États-Unis] ; Xiaodong Xiao ; Lisa E. Hensley [États-Unis] ; Ponraj Prabakaran ; Barry Rockx [États-Unis] ; Igor A. Sidorov ; Davide Corti ; Leatrice Vogel ; Yang Feng ; Jae-Ouk Kim [États-Unis] ; Lin-Fa Wang [Australie] ; Ralph Baric [États-Unis] ; Antonio Lanzavecchia ; Kristopher M. Curtis [États-Unis] ; Gary J. Nabel [États-Unis] ; Kanta Subbarao ; Shibo Jiang [États-Unis] ; Dimiter S. DimitrovSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2007.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (immunologie), Fixation compétitive, Flambées de maladies, Fusion cellulaire, Humains, Modèles animaux de maladie humaine, Modèles biologiques, Modèles moléculaires, Mutagenèse, Nandiniidae (virologie), Protéines virales (métabolisme), Pénétration virale, Réactions croisées, Récepteurs de surface cellulaire (), Réplication virale, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Syndrome respiratoire aigu sévère (épidémiologie), Tests de neutralisation, Virus du SRAS (immunologie), Virus du SRAS (isolement et purification), Virus du SRAS (physiologie).
- MESH :
- immunologie : Anticorps monoclonaux, Syndrome respiratoire aigu sévère, Virus du SRAS.
- isolement et purification : Virus du SRAS.
- métabolisme : Protéines virales.
- physiologie : Virus du SRAS.
- virologie : Nandiniidae, Syndrome respiratoire aigu sévère.
- épidémiologie : Syndrome respiratoire aigu sévère.
- Animaux, Fixation compétitive, Flambées de maladies, Fusion cellulaire, Humains, Modèles animaux de maladie humaine, Modèles biologiques, Modèles moléculaires, Mutagenèse, Pénétration virale, Réactions croisées, Récepteurs de surface cellulaire, Réplication virale, Structure tertiaire des protéines, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Binding, Competitive, Cell Fusion, Cross Reactions, Disease Models, Animal, Disease Outbreaks, Humans, Models, Biological, Models, Molecular, Mutagenesis, Nandiniidae (virology), Neutralization Tests, Protein Structure, Tertiary, Receptors, Cell Surface (chemistry), SARS Virus (immunology), SARS Virus (isolation & purification), SARS Virus (physiology), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Viral Proteins (metabolism), Virus Internalization, Virus Replication.
- MESH :
- chemical , chemistry : Receptors, Cell Surface.
- chemical , immunology : Antibodies, Monoclonal.
- epidemiology : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- isolation & purification : SARS Virus.
- chemical , metabolism : Viral Proteins.
- physiology : SARS Virus.
- virology : Nandiniidae, Severe Acute Respiratory Syndrome.
- Animals, Binding, Competitive, Cell Fusion, Cross Reactions, Disease Models, Animal, Disease Outbreaks, Humans, Models, Biological, Models, Molecular, Mutagenesis, Neutralization Tests, Protein Structure, Tertiary, Virus Internalization, Virus Replication.
Abstract
The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV–ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.
Url:
DOI: 10.1073/pnas.0701000104
PubMed: 17620608
PubMed Central: 1924550
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000D23
- to stream Pmc, to step Curation: 000D23
- to stream Pmc, to step Checkpoint: 000F18
- to stream PubMed, to step Corpus: 001D70
- to stream PubMed, to step Curation: 001D70
- to stream PubMed, to step Checkpoint: 001D36
- to stream Ncbi, to step Merge: 001A14
- to stream Ncbi, to step Curation: 001A14
- to stream Ncbi, to step Checkpoint: 001A14
- to stream Main, to step Merge: 003761
- to stream Main, to step Curation: 003634
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation><affiliation wicri:level="2"><nlm:aff id="aff2">Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="Chakraborti, Samitabh" sort="Chakraborti, Samitabh" uniqKey="Chakraborti S" first="Samitabh" last="Chakraborti">Samitabh Chakraborti</name><affiliation wicri:level="2"><nlm:aff id="aff2">Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><affiliation wicri:level="2"><nlm:aff id="aff3">Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation><nlm:aff wicri:cut=" and" id="aff4">Laboratory of Infectious Diseases</nlm:aff></affiliation></author><author><name sortKey="Sheahan, Tim" sort="Sheahan, Tim" uniqKey="Sheahan T" first="Tim" last="Sheahan">Tim Sheahan</name><affiliation wicri:level="2"><nlm:aff id="aff6">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Xiao, Xiaodong" sort="Xiao, Xiaodong" uniqKey="Xiao X" first="Xiaodong" last="Xiao">Xiaodong Xiao</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E." last="Hensley">Lisa E. Hensley</name><affiliation wicri:level="2"><nlm:aff id="aff7">Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick</wicri:cityArea></affiliation></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name><affiliation wicri:level="2"><nlm:aff id="aff6">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Sidorov, Igor A" sort="Sidorov, Igor A" uniqKey="Sidorov I" first="Igor A." last="Sidorov">Igor A. Sidorov</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation><nlm:aff id="aff8">**Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland; and</nlm:aff><wicri:noCountry code="subfield">Switzerland; and</wicri:noCountry></affiliation></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><affiliation><nlm:aff wicri:cut=" and" id="aff4">Laboratory of Infectious Diseases</nlm:aff></affiliation></author><author><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name><affiliation wicri:level="2"><nlm:aff id="aff5">Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Lin Fa" sort="Wang, Lin Fa" uniqKey="Wang L" first="Lin-Fa" last="Wang">Lin-Fa Wang</name><affiliation wicri:level="1"><nlm:aff id="aff9">CSIRO Livestock Industries, Australian Animal Health Laboratory and Australian Biosecurity Cooperative Research Center for Emerging Infectious Diseases, Geelong, Victoria 3220, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>CSIRO Livestock Industries, Australian Animal Health Laboratory and Australian Biosecurity Cooperative Research Center for Emerging Infectious Diseases, Geelong, Victoria 3220</wicri:regionArea><wicri:noRegion>Victoria 3220</wicri:noRegion></affiliation></author><author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name><affiliation wicri:level="2"><nlm:aff id="aff6">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation><nlm:aff id="aff8">**Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland; and</nlm:aff><wicri:noCountry code="subfield">Switzerland; and</wicri:noCountry></affiliation></author><author><name sortKey="Curtis, Kristopher M" sort="Curtis, Kristopher M" uniqKey="Curtis K" first="Kristopher M." last="Curtis">Kristopher M. Curtis</name><affiliation wicri:level="2"><nlm:aff id="aff7">Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick</wicri:cityArea></affiliation></author><author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J." last="Nabel">Gary J. Nabel</name><affiliation wicri:level="2"><nlm:aff id="aff5">Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><nlm:aff wicri:cut=" and" id="aff4">Laboratory of Infectious Diseases</nlm:aff></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:aff id="aff3">Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S." last="Dimitrov">Dimiter S. Dimitrov</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17620608</idno><idno type="pmc">1924550</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924550</idno><idno type="RBID">PMC:1924550</idno><idno type="doi">10.1073/pnas.0701000104</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">000D23</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D23</idno><idno type="wicri:Area/Pmc/Curation">000D23</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000D23</idno><idno type="wicri:Area/Pmc/Checkpoint">000F18</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F18</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17620608</idno><idno type="wicri:Area/PubMed/Corpus">001D70</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D70</idno><idno type="wicri:Area/PubMed/Curation">001D70</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D70</idno><idno type="wicri:Area/PubMed/Checkpoint">001D36</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D36</idno><idno type="wicri:Area/Ncbi/Merge">001A14</idno><idno type="wicri:Area/Ncbi/Curation">001A14</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A14</idno><idno type="wicri:doubleKey">0027-8424:2007:Zhu Z:potent:cross:reactive</idno><idno type="wicri:Area/Main/Merge">003761</idno><idno type="wicri:Area/Main/Curation">003634</idno><idno type="wicri:Area/Main/Exploration">003634</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation><affiliation wicri:level="2"><nlm:aff id="aff2">Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="Chakraborti, Samitabh" sort="Chakraborti, Samitabh" uniqKey="Chakraborti S" first="Samitabh" last="Chakraborti">Samitabh Chakraborti</name><affiliation wicri:level="2"><nlm:aff id="aff2">Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick</wicri:cityArea></affiliation></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><affiliation wicri:level="2"><nlm:aff id="aff3">Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation><nlm:aff wicri:cut=" and" id="aff4">Laboratory of Infectious Diseases</nlm:aff></affiliation></author><author><name sortKey="Sheahan, Tim" sort="Sheahan, Tim" uniqKey="Sheahan T" first="Tim" last="Sheahan">Tim Sheahan</name><affiliation wicri:level="2"><nlm:aff id="aff6">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Xiao, Xiaodong" sort="Xiao, Xiaodong" uniqKey="Xiao X" first="Xiaodong" last="Xiao">Xiaodong Xiao</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E." last="Hensley">Lisa E. Hensley</name><affiliation wicri:level="2"><nlm:aff id="aff7">Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick</wicri:cityArea></affiliation></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name><affiliation wicri:level="2"><nlm:aff id="aff6">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Sidorov, Igor A" sort="Sidorov, Igor A" uniqKey="Sidorov I" first="Igor A." last="Sidorov">Igor A. Sidorov</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation><nlm:aff id="aff8">**Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland; and</nlm:aff><wicri:noCountry code="subfield">Switzerland; and</wicri:noCountry></affiliation></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><affiliation><nlm:aff wicri:cut=" and" id="aff4">Laboratory of Infectious Diseases</nlm:aff></affiliation></author><author><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author><author><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name><affiliation wicri:level="2"><nlm:aff id="aff5">Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Lin Fa" sort="Wang, Lin Fa" uniqKey="Wang L" first="Lin-Fa" last="Wang">Lin-Fa Wang</name><affiliation wicri:level="1"><nlm:aff id="aff9">CSIRO Livestock Industries, Australian Animal Health Laboratory and Australian Biosecurity Cooperative Research Center for Emerging Infectious Diseases, Geelong, Victoria 3220, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>CSIRO Livestock Industries, Australian Animal Health Laboratory and Australian Biosecurity Cooperative Research Center for Emerging Infectious Diseases, Geelong, Victoria 3220</wicri:regionArea><wicri:noRegion>Victoria 3220</wicri:noRegion></affiliation></author><author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name><affiliation wicri:level="2"><nlm:aff id="aff6">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation><nlm:aff id="aff8">**Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland; and</nlm:aff><wicri:noCountry code="subfield">Switzerland; and</wicri:noCountry></affiliation></author><author><name sortKey="Curtis, Kristopher M" sort="Curtis, Kristopher M" uniqKey="Curtis K" first="Kristopher M." last="Curtis">Kristopher M. Curtis</name><affiliation wicri:level="2"><nlm:aff id="aff7">Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick</wicri:cityArea></affiliation></author><author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J." last="Nabel">Gary J. Nabel</name><affiliation wicri:level="2"><nlm:aff id="aff5">Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><nlm:aff wicri:cut=" and" id="aff4">Laboratory of Infectious Diseases</nlm:aff></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:aff id="aff3">Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S." last="Dimitrov">Dimiter S. Dimitrov</name><affiliation><nlm:aff id="aff1">*Protein Interactions Group, Center for Cancer Research Nanobiology Program, and</nlm:aff><wicri:noCountry code="subfield">and</wicri:noCountry></affiliation></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><idno type="eISSN">1091-6490</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Binding, Competitive</term><term>Cell Fusion</term><term>Cross Reactions</term><term>Disease Models, Animal</term><term>Disease Outbreaks</term><term>Humans</term><term>Models, Biological</term><term>Models, Molecular</term><term>Mutagenesis</term><term>Nandiniidae (virology)</term><term>Neutralization Tests</term><term>Protein Structure, Tertiary</term><term>Receptors, Cell Surface (chemistry)</term><term>SARS Virus (immunology)</term><term>SARS Virus (isolation & purification)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Viral Proteins (metabolism)</term><term>Virus Internalization</term><term>Virus Replication</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (immunologie)</term><term>Fixation compétitive</term><term>Flambées de maladies</term><term>Fusion cellulaire</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Modèles biologiques</term><term>Modèles moléculaires</term><term>Mutagenèse</term><term>Nandiniidae (virologie)</term><term>Protéines virales (métabolisme)</term><term>Pénétration virale</term><term>Réactions croisées</term><term>Récepteurs de surface cellulaire ()</term><term>Réplication virale</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (isolement et purification)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Receptors, Cell Surface</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Nandiniidae</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Nandiniidae</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Binding, Competitive</term><term>Cell Fusion</term><term>Cross Reactions</term><term>Disease Models, Animal</term><term>Disease Outbreaks</term><term>Humans</term><term>Models, Biological</term><term>Models, Molecular</term><term>Mutagenesis</term><term>Neutralization Tests</term><term>Protein Structure, Tertiary</term><term>Virus Internalization</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Fixation compétitive</term><term>Flambées de maladies</term><term>Fusion cellulaire</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Modèles biologiques</term><term>Modèles moléculaires</term><term>Mutagenèse</term><term>Pénétration virale</term><term>Réactions croisées</term><term>Récepteurs de surface cellulaire</term><term>Réplication virale</term><term>Structure tertiaire des protéines</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV–ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.</p></div></front></TEI><affiliations><list><country><li>Australie</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Maryland</li><li>État de New York</li></region></list><tree><noCountry><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S." last="Dimitrov">Dimiter S. Dimitrov</name><name sortKey="Feng, Yang" sort="Feng, Yang" uniqKey="Feng Y" first="Yang" last="Feng">Yang Feng</name><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><name sortKey="Sidorov, Igor A" sort="Sidorov, Igor A" uniqKey="Sidorov I" first="Igor A." last="Sidorov">Igor A. Sidorov</name><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><name sortKey="Xiao, Xiaodong" sort="Xiao, Xiaodong" uniqKey="Xiao X" first="Xiaodong" last="Xiao">Xiaodong Xiao</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name></region><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name><name sortKey="Chakraborti, Samitabh" sort="Chakraborti, Samitabh" uniqKey="Chakraborti S" first="Samitabh" last="Chakraborti">Samitabh Chakraborti</name><name sortKey="Curtis, Kristopher M" sort="Curtis, Kristopher M" uniqKey="Curtis K" first="Kristopher M." last="Curtis">Kristopher M. Curtis</name><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E." last="Hensley">Lisa E. Hensley</name><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J." last="Nabel">Gary J. Nabel</name><name sortKey="Rockx, Barry" sort="Rockx, Barry" uniqKey="Rockx B" first="Barry" last="Rockx">Barry Rockx</name><name sortKey="Sheahan, Tim" sort="Sheahan, Tim" uniqKey="Sheahan T" first="Tim" last="Sheahan">Tim Sheahan</name></country><country name="Australie"><noRegion><name sortKey="Wang, Lin Fa" sort="Wang, Lin Fa" uniqKey="Wang L" first="Lin-Fa" last="Wang">Lin-Fa Wang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003634 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003634 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:1924550
|texte= Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17620608" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |